Physician profile
John Boulos
NPI 1790029072
$4,439.04
in general payments reported to CMS, 2019-2025
15 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $196 · 2021: $554 · 2022: $558 · 2023: $357 · 2024: $2,216 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Travel and Lodging: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.18 |
| Travel and Lodging | $1,328.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $2,089.56 | 2024 | |
| Stryker Corporation | $1,509.58 | 2019-2025 | Variax, Actishield, Augment Injectable |
| Organogenesis INC. | $231.58 | 2020-2023 | Puraply |
| Abbott Laboratories | $106.52 | 2022 | |
| Amgen INC. | $104.82 | 2024-2025 | Krystexxa |
| Smith+Nephew, INC. | $103.00 | 2019-2024 | Collagenase Santyl, Regranex |
| Paratek Pharmaceuticals, INC. | $99.02 | 2024-2025 | Nuzyra |
| Bioventus LLC | $35.38 | 2022 | |
| Nevro Corp. | $32.53 | 2022 | |
| Grt US Holding, INC. | $30.93 | 2022 | |
| Averitas Pharma INC. | $24.72 | 2024 | Qutenza |
| Zimmer Biomet Holdings, INC. | $21.55 | 2021 | |
| Treace Medical Concepts, INC. | $20.13 | 2022 | |
| Medtronic, INC. | $15.22 | 2024 | Intellis Adaptivestim |
| Alexion Pharmaceuticals, INC. | $14.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Boulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.